A phase I clinical trial of SYNB1618 for the treatment of phenylketonuria (PKU)

Trial Profile

A phase I clinical trial of SYNB1618 for the treatment of phenylketonuria (PKU)

Planning
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs SYNB-1618 (Primary)
  • Indications Phenylketonuria
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Aug 2017 New trial record
    • 28 Aug 2017 This trial is expected to begin in the first half of 2018, according to a Synlogic media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top